SLC26A4 and Hodgkins lymphoma: They also identify the potential of interfering with the SLC26A4-μ2 interaction for therapeutic purposes in the inner ear to increase hypofunctional SLC26A4 cell surface abundance and function in patients with such pathogenic variants associated with one of the most frequent forms of HL worldwide.